• This record comes from PubMed

Interleukin 6 and complement serum level study in Parkinson's disease

. 2018 May ; 125 (5) : 875-881. [epub] 20180212

Language English Country Austria Media print-electronic

Document type Journal Article, Research Support, Non-U.S. Gov't

Links

PubMed 29435648
DOI 10.1007/s00702-018-1857-5
PII: 10.1007/s00702-018-1857-5
Knihovny.cz E-resources

The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson's disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.

See more in PubMed

J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4 PubMed

Neurology. 1967 May;17(5):427-42 PubMed

Int Immunol. 2015 Jan;27(1):21-9 PubMed

J Neurol. 2010 Apr;257(4):524-32 PubMed

Parkinsonism Relat Disord. 2009 May;15(4):318-20 PubMed

Parkinsonism Relat Disord. 2015 Oct;21(10 ):1219-26 PubMed

Ann N Y Acad Sci. 2009 Feb;1153:220-39 PubMed

Brain Behav Immun. 2013 Oct;33:183-9 PubMed

Eur J Neurol. 2009 Jan;16(1):142-7 PubMed

Neurochem Res. 2009 Aug;34(8):1401-4 PubMed

Clin Neurosci Res. 2006 Aug;6(1-2):52-68 PubMed

PLoS One. 2012;7(10):e47387 PubMed

Arch Neurol. 2003 Aug;60(8):1059-64 PubMed

Curr Opin Pharmacol. 2016 Feb;26:87-95 PubMed

Neurosci Lett. 2008 Aug 22;441(2):158-62 PubMed

PLoS One. 2015 Aug 26;10(8):e0136722 PubMed

Neurosci Lett. 1996 Jun 14;211(1):13-6 PubMed

Mov Disord. 2016 Jul;31(7):995-1003 PubMed

Md State Med J. 1965 Feb;14:61-5 PubMed

Nat Rev Neurosci. 2008 Jan;9(1):46-56 PubMed

J Psychiatr Res. 1975 Nov;12(3):189-98 PubMed

Br J Psychiatry. 1979 Apr;134:382-9 PubMed

Neurosci Lett. 2010 Jan 1;468(1):56-8 PubMed

Acta Neurol Scand. 1998 Aug;98(2):142-4 PubMed

Mol Immunol. 2007 Feb;44(5):999-1010 PubMed

Neurosci Lett. 1994 Oct 24;180(2):147-50 PubMed

Gerontologist. 1969 Autumn;9(3):179-86 PubMed

JAMA Neurol. 2016 Nov 1;73(11):1316-1324 PubMed

Dis Markers. 2005;21(2):93-101 PubMed

Acta Neurol Scand. 1999 Jul;100(1):34-41 PubMed

Acta Neuropathol. 1992;84(1):100-4 PubMed

Parkinsons Dis. 2015;2015:898192 PubMed

Brain Res. 1996 Jan 29;707(2):196-205 PubMed

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...